Aerovate Therapeutics, Inc. AVTE
Institutional shares held
20.3 Million
0
calls
0
puts
Total value of holdings
$346M
$0
calls
$0
puts
Market Cap
$418M
24,448,100
Shares Out.
Institutional ownership
82.85%
# of Institutions
81
We take great care to ensure that the data presented and summarized in this overview for Aerovate Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVTE
View all-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$64.2 Million6.47% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.2MShares$37.6 Million6.85% of portfolio
-
Atlas Venture Life Science Advisors, LLC2.04MShares$34.9 Million7.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.68MShares$28.7 Million0.63% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.2MShares$20.6 Million1.87% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.07MShares$18.3 Million1.82% of portfolio
-
Great Point Partners LLC Greenwich, CT888KShares$15.2 Million6.42% of portfolio
-
Driehaus Capital Management LLC Chicago, IL795KShares$13.6 Million0.26% of portfolio
-
Black Rock Inc. New York, NY710KShares$12.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA672KShares$11.5 Million0.0% of portfolio
Latest Institutional Activity in AVTE
Top Purchases
Top Sells
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Transactions at AVTE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-21.14%
|
$84,000
$21.47 P/Share
|
|
May 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+29.41%
|
$8,000
$2.14 P/Share
|
|
May 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-93.54%
|
$210,000
$21.72 P/Share
|
|
May 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.14 P/Share
|
|
May 02
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,981
-100.0%
|
$41,601
$21.02 P/Share
|
|
May 01
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,357
-96.78%
|
$227,140
$20.37 P/Share
|
|
May 01
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.14 P/Share
|
|
Apr 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-29.8%
|
$88,000
$22.82 P/Share
|
|
Apr 17
2024
|
Hunter Gillies CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+35.55%
|
$4,000
$1.74 P/Share
|
|
Apr 17
2024
|
Benjamin T Dake |
SELL
Open market or private sale
|
Direct |
6,853
-34.69%
|
$157,619
$23.15 P/Share
|
|
Apr 17
2024
|
Benjamin T Dake |
BUY
Exercise of conversion of derivative security
|
Direct |
6,853
+45.7%
|
$13,706
$2.14 P/Share
|
|
Apr 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-72.46%
|
$240,000
$24.67 P/Share
|
|
Apr 16
2024
|
Timothy P Noyes CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.14 P/Share
|
|
Apr 10
2024
|
George A Eldridge |
SELL
Open market or private sale
|
Direct |
7,500
-49.68%
|
$202,500
$27.17 P/Share
|
|
Apr 10
2024
|
George A Eldridge |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+44.22%
|
$15,000
$2.14 P/Share
|
|
Apr 09
2024
|
David S. Grayzel |
SELL
Open market or private sale
|
Indirect |
11,882
-45.03%
|
$332,696
$28.15 P/Share
|
|
Apr 01
2024
|
George A Eldridge |
SELL
Open market or private sale
|
Direct |
12,495
-86.44%
|
$387,345
$31.23 P/Share
|
|
Apr 01
2024
|
George A Eldridge |
BUY
Exercise of conversion of derivative security
|
Direct |
12,495
+46.36%
|
$24,990
$2.14 P/Share
|
|
Apr 01
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,300
-85.81%
|
$153,700
$29.44 P/Share
|
|
Apr 01
2024
|
Marinus Verwijs CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+50.0%
|
$74,200
$14.59 P/Share
|
Last 12 Months Summary
Buy / Acquisition
342K
Shares
From
6
Insiders
| Exercise of conversion of derivative security | 342K shares |
|---|
Sell / Disposition
359K
Shares
From
7
Insiders
| Open market or private sale | 359K shares |
|---|